Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite vs. iStent Infinite Alone in Subjects With Open-angle Glaucoma or Ocular Hypertension
Latest Information Update: 30 Jan 2026
At a glance
- Drugs Travoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Sponsors Glaukos Corporation
Most Recent Events
- 21 Jan 2026 Planned number of patients changed from 150 to 230.
- 21 Jan 2026 Planned End Date changed from 1 Nov 2025 to 1 Feb 2028.
- 21 Jan 2026 Planned primary completion date changed from 1 Feb 2025 to 1 May 2027.